Generate Biomedicines Inc (GENB)

May 01, 2026

Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

May 01, 2026

Apr 27, 2026

GENB Generate Biomedicines leadership flags accelerated AI drug pipeline advancement as top priority in latest quarterly earnings update.Revenue Guidance - Newser

Apr 27, 2026

Apr 27, 2026

Generate Biomedicines (GENB) Stock Public Float (Smart Money Outflows) 2026-04-27IPO Watch - Newser

Apr 27, 2026

Apr 24, 2026

GENB Price History for Generate Biomedicines Stock - Barchart.com

Apr 24, 2026

Apr 21, 2026

Generate Biomedicines Inc (GENB) Stock Price, Quote, News & History - Benzinga

Apr 21, 2026

Apr 20, 2026

Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat

Apr 20, 2026

Apr 19, 2026

H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating - insidermonkey.com

Apr 19, 2026

Apr 18, 2026

Generate Biomedicines (GENB) Stock: Investment Analysis (Grinds Lower) 2026-04-18High Attention Stocks - Newser

Apr 18, 2026

Apr 17, 2026

GENB Stock Price, News & Analysis - Stock Titan

Apr 17, 2026

Apr 14, 2026

Preferred dividends of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Apr 14, 2026

Apr 14, 2026

GENB Forecast — Price Target — Prediction for 2027 - TradingView

Apr 14, 2026

Apr 14, 2026

Generate Biomedicines, Inc. News — NASDAQ:GENB - TradingView

Apr 14, 2026

Apr 14, 2026

Long term debt to total equity ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView — Track All Markets

Apr 14, 2026

Apr 14, 2026

Preferred dividends of Generate Biomedicines, Inc. – BX:GENB - TradingView — Track All Markets

Apr 14, 2026

Apr 14, 2026

This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm

Apr 14, 2026

Apr 13, 2026

GENB Price Today: Generate Biomedicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC

Apr 13, 2026

Apr 13, 2026

GENB Initiated Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus

Apr 13, 2026

Apr 13, 2026

HC Wainwright Initiates Generate Biomedicines at Buy With $16 Price Target - marketscreener.com

Apr 13, 2026

Apr 09, 2026

IPO Tracker 2026: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic - BioSpace

Apr 09, 2026

Apr 07, 2026

Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.

Apr 07, 2026

Apr 06, 2026

Will Generate Biomedicines (GENB) Stock Hit Record Highs | Price at $12.10, Down 12.00%Community Buy Alerts - Newser

Apr 06, 2026

Apr 03, 2026

Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat

Apr 03, 2026

Apr 02, 2026

Cantor Fitzgerald reiterates Generate Biomedicines stock rating By Investing.com - Investing.com Canada

Apr 02, 2026

Apr 02, 2026

GENB | Generate Biomedicines, Inc. Common Analyst Forecasts - Quiver Quantitative

Apr 02, 2026

Mar 30, 2026

IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace

Mar 30, 2026

Mar 27, 2026

Kailera Therapeutics files for US IPO - MarketScreener

Mar 27, 2026

Mar 27, 2026

Flagship-backed Generate Bio seeks $425 million in US IPO - MSN

Mar 27, 2026

Mar 27, 2026

Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Zacks Research - MarketBeat

Mar 27, 2026

Mar 26, 2026

Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent

Mar 26, 2026

Mar 25, 2026

This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm

Mar 25, 2026

Mar 24, 2026

Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler - MSN

Mar 24, 2026

Mar 24, 2026

The Goldman Sachs Group Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - MarketBeat

Mar 24, 2026

Mar 24, 2026

Morgan Stanley Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - marketbeat.com

Mar 24, 2026

Mar 24, 2026

Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim - marketbeat.com

Mar 24, 2026

Mar 24, 2026

Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat

Mar 24, 2026

Mar 24, 2026

Goldman Sachs Initiates Coverage on Generate Biomedicines With Buy Rating, $26 Price Target - marketscreener.com

Mar 24, 2026

Mar 24, 2026

Guggenheim Initiates Coverage on Generate Biomedicines With Buy Rating, $30 Price Target - marketscreener.com

Mar 24, 2026

Mar 24, 2026

Piper Sandler initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada

Mar 24, 2026

Mar 24, 2026

Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target - marketscreener.com

Mar 24, 2026

Mar 24, 2026

Morgan Stanley initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada

Mar 24, 2026

Mar 24, 2026

Piper Sandler initiates Generate Biomedicines stock at overweight - Investing.com

Mar 24, 2026

Mar 24, 2026

Morgan Stanley initiates Generate Biomedicines stock at overweight - Investing.com

Mar 24, 2026

Mar 24, 2026

Goldman Sachs initiates Generate Biomedicines stock with buy rating on AI platform potential - Investing.com

Mar 24, 2026

Mar 24, 2026

Guggenheim initiates Generate Biomedicines stock with buy rating By Investing.com - Investing.com Australia

Mar 24, 2026

Mar 24, 2026

Guggenheim initiates Generate Biomedicines stock with buy rating - investing.com

Mar 24, 2026

Mar 22, 2026

ETFs Investing in Generate Biomedicines, Inc. Stocks - TradingView — Track All Markets

Mar 22, 2026

Mar 19, 2026

Generate Biomedicines IPO Turns Heads - Yahoo! Finance Canada

Mar 19, 2026

Mar 18, 2026

Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat

Mar 18, 2026